Tatratrial s.r.o. — Clinical Trial Site

20 Registered trials

4 Currently recruiting

Organisation

Tatratrial s.r.o.

Location

Roznava, Slovakia

Identifier

ORG-100045322

Address

Namestie 1. Maja 11, 048 01, Slovakia

Departments

3029; Ambulancia diabetológie a porúch látkovej premeny a výživy
Ambulancia diabetologie a poruch latkovej premeny a vyzivy
DIAB s.r.o., Clinic for diabetes and metabolic and nutritional disorders
NA
Outpatient care for diabetology and metabolic disorders and nutrition
Outpatient Clinic for Diabetology, Metabolism and Nutrition Disorders

Clinical trials at this site (20)

Search interface

EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M… Ended

2024-512562-34-00 Type 2 Diabetes Mellitus 4 2025-02-24
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Chronic Kidney Disease, Type 2 diabetes 4 2024-04-19
A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended

2023-506197-12-00 Dyslipidemia Dyslipidemias are alterations to the plasm 4 2024-02-07
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Obesity 5 2023-09-05
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended

2024-510612-75-00 Participants with T2D and overweight 5 2022-08-31
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19